ABP 501 (adalimumab-atto) in the treatment of inflammatory bowel disease: an example of evidence-based extrapolation
We report the available evidence demonstrating the biosimilarity of ABP 501 (AMGEVITA®, adalimumab-atto) to its reference product (RP) (Humira®, adalimumab), and the rationale for the extrapolation of the results obtained with the RP in inflammatory bowel disease (IBD) to ABP 501.
Saved in:
| Published in | Revista española de enfermedades digestivas Vol. 113; no. 10; pp. 737 - 738 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
Spain
Sociedad Espanola de Patologia Digestivas
01.10.2021
|
| Online Access | Get full text |
Cover
Loading…
| Summary: | We report the available evidence demonstrating the biosimilarity of ABP 501 (AMGEVITA®, adalimumab-atto) to its reference product (RP) (Humira®, adalimumab), and the rationale for the extrapolation of the results obtained with the RP in inflammatory bowel disease (IBD) to ABP 501. |
|---|---|
| Bibliography: | SourceType-Other Sources-1 content type line 63 ObjectType-Correspondence-1 |
| ISSN: | 1130-0108 |
| DOI: | 10.17235/reed.2021.7921/2021 |